Clobenzorex

Summary

Clobenzorex (CHEMBL1213251) is an approved small molecule (ATC A08AA08); indicated across 1 condition including obesity disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A08AA08
• Indications: 1 condition
• Chemistry: 259.77 Da · C16H18ClN

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1213251
Name	Clobenzorex
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	71675
ATC	A08AA08
Molecular formula	C16H18ClN
Molecular weight	259.77
InChIKey	LRXXRIXDSAEIOR-UHFFFAOYSA-N

SMILES: CC(CC1=CC=CC=C1)NCC2=CC=CC=C2Cl

IUPAC name: N-[(2-chlorophenyl)methyl]-1-phenylpropan-2-amine

Also known as: Clobenzorex, SD-27112, SID29216105, CLOBENZOREX

Parent form; salt/anhydrous children: CHEMBL2360490

Patent coverage: 700 distinct patent families (3,055 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,052 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prelamin-A/C.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	6.75	Potency	177.8	nM	CHEMBL_ACT_3621848

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
obesity disorder	4	MONDO:0011122	EFO:0001073

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).